Talicia Holding

RedHill Biopharma is a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal (GI) diseases and infectious diseases. The company's flagship product is Talicia, an FDA-approved fixed-dose combination of omeprazole, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults. RedHill also markets Aemcolo for travelers' diarrhea and maintains a robust clinical pipeline targeting conditions such as Crohn's disease, nontuberculous mycobacteria (NTM) infections, and various gastrointestinal cancers. Headquartered in Israel with a significant U.S. presence, the company leverages its commercial infrastructure to bring novel therapeutic solutions to market while advancing late-stage clinical candidates.